Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | KK2269 |
Synonyms | |
Therapy Description |
KK2269 is a bispecific antibody that targets CD40 expressed on antigen presenting cells (APCs) and EPCAM expressed on tumor cells, resulting in EPCAM-dependent activation of CD40 signaling, which potentially enhances antitumor immune response and delays tumor growth (Cancer Res (2024) 84 (6_Supplement): 5310; Cancer Res (2024) 84 (6_Supplement): 5311). |